Bardoxolone methyl , an Nrf2-activating and nuclear factor-B-inhibiting semisynthetic oleanane triterpenoid compound , was evaluated in a phase 3 trial ( BEACON ) in patients with type 2 diabetes mellitus ( T2DM ) and stage 4 chronic kidney disease ( CKD ) .